US4562003A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Monoclonal antibodies against alveolar surfactant protein
Assignee: Takeda GmbH
•
Filing: 1984-10-26
•
Granted: 1985-12-31
•
Expires: 2004-10-26
Abstract
Abstract Monoclonal antibodies specific for a protein associated with a lung surfactant complex, decreased levels of which are related to respiratory distress syndrome, are disclosed. The antibodies are useful for prediction and diagnosis of respiratory problems in newborns.
Inventors
- 👤 John Lewicki
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:48
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/68; G01N33/6884; C; C07; C07K; C07K16/00; C07K16/18; Y; Y10; Y10S; Y10S435/00; Y10S435/81; Y10S435/8215; Y10S435/948; Y10S435/975; Y10S436/00; Y10S436/807; Y10S436/808; Y10S530/00; Y10S530/808; Y10S530/809
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
10 words
Monoclonal antibody (Mab) specific against human alveolar surfactant protein (ASP).
Claim 2
Dependent Claim
10 words
Monoclonal antibody (Mab) specific against human alveolar surfactant protein (ASP).
Claim 3
Dependent Claim
20 words
The Mab of claim 1 which is produced by a hybridoma cell line screened for anti-ASP activity against non-human ASP.
Claim 4
Dependent Claim
11 words
The Mab of claim 1 which is of the class IgG1.
Claim 5
Dependent Claim
11 words
The Mab of claim 1 which is of the class IgG2A.
Claim 6
Dependent Claim
28 words
The Mab of claim 2 wherein the hybridoma is prepared by fusing an immortalizing cell line with spleen cells derived from a mammal immunized with purified canine ASP.
Claim 7
Dependent Claim
14 words
The Mab of claim 5 wherein the immortalizing cell is a murine myeloma line.
Claim 8
Dependent Claim
19 words
The Mab of claim 6, wherein the hybridoma is selected from the group consisting of DS-3, DS-5, and DS-6.
Claim 9
Dependent Claim
12 words
A hybridoma cell line capable of secreting antibodies specific for human ASP.
Claim 10
Dependent Claim
12 words
A hybridoma cell line capable of secreting antibodies specific for human ASP.
Claim 11
Dependent Claim
26 words
The hybridoma of claim 8 which is prepared by fusing an immortalizing cell line with spleen cells derived from a mammal immunized with purified canine ASP.
Claim 12
Dependent Claim
14 words
The hybridoma of claim 9 wherein the immortalizing cell is a murine myeloma line.
Claim 13
Dependent Claim
17 words
The hybridoma of claim 10, which is selected from the group consisting of DS-3, DS-5, and DS-6.
Claim 14
Dependent Claim
17 words
A method of producing monoclonal antibodies specific for ASP which comprises culturing the hybridoma of claim 8.
Claim 15
Dependent Claim
19 words
The method of claim 12, wherein the hybridoma is selected from the group consisting of DS-3, DS-5, and DS-6.
Claim 16
Dependent Claim
8 words
Mab prepared by the method of claim 12.
Claim 17
Dependent Claim
32 words
A method of preparing Mab specific for ASP which comprises injecting into a mouse the hybridoma of claim 8 and recovering the Mab from the malignant ascites or serum of the mouse.
Claim 18
Dependent Claim
19 words
The method of claim 15, wherein the hybridoma is selected from the group consisting of DS-3, DS-5, and DS-6.
Claim 19
Dependent Claim
8 words
Mab prepared by the method of claim 15.
Claim 20
Dependent Claim
26 words
A method of detecting the presence of human ASP in a biological sample which method comprises treating said sample with the monoclonal antibody of claim 1.
Claim 21
Dependent Claim
12 words
The method of claim 18 wherein the biological sample is amniotic fluid.
Claim 22
Dependent Claim
41 words
A method of detecting the presence of human ASP in a biological sample which method comprises: (a) immobilizing the Mab of claim 1; (b) treating the sample with the immobilized Mab; and (c) observing the degree of agglutination produced in (b).
Claim 23
Dependent Claim
84 words
A method of detecting the presence of human ASP in a biological sample which method comprises: (a) immobilizing the Mab of claim 1 on a solid phase support; (b) treating the sample with the immobilized Mab; (c) treating the mixture of (b) with a second Mab of claim 1, which Mab is specific for a different ASP epitope, and which Mab has been labeled; (d) separating solid phase from liquid phase; and (e) detecting the amount of label in the solid or liquid phase.
Claim 24
Dependent Claim
21 words
A test kit for assessing the level of human ASP in a biological sample which comprises the Mab of claim 1.
Claim 25
Dependent Claim
26 words
A test kit for determining fetal lung development by assessing the level of human ASP in amniotic fluid which kit comprises the Mab of claim 1.
References Cited (Backward Citations)
US4364934A
Cited
US4364936A
Cited
US4472500A
Cited
US4486530A
Cited
US4427653A
Cited
US4471058A
Cited
US4517289A
Cited
US4474892A
Cited
US4469630A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-12-30 | 1989-07-01 | 1989-12-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-12-30 | 1993-07-01 | 1993-12-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-12-30 | 1997-07-01 | 1997-12-31 | $7700.00 | Window Closed / Lapsed |